Long‐Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine: Phase 3, Randomized, 52‐Week Extension Trial-Reference-Cited by-同舟云学术

Long‐Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine: Phase 3, Randomized, 52‐Week Extension Trial

Published:2020-01 Issue:1 Volume:60 Page:141-152
ISSN:0017-8748
Container-title:Headache: The Journal of Head and Face Pain
language:en
Short-container-title:Headache: The Journal of Head and Face Pain

Author:

Ailani Jessica¹,Lipton Richard B.²,Hutchinson Susan³,Knievel Kerry⁴,Lu Kaifeng⁵,Butler Matthew⁵,Yu Sung Yun⁵,Finnegan Michelle⁵,Severt Lawrence⁵,Trugman Joel M.⁵

Affiliation:

1. Medstar Georgetown University Hospital Washington DC USA

2. Albert Einstein College of Medicine and Montefiore Headache Center Bronx NY USA

3. Orange County Migraine & Headache Center Irvine CA USA

4. Barrow Neurological Institute Phoenix AZ USA

5. Allergan plc Madison NJ USA

Funder

Allergan

Publisher

Wiley

Subject

Neurology (clinical),Neurology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/head.13682

Reference32 articles.

1. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition

2. Global, regional, and national burden of neurological disorders during 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015

3. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016

4. Migraine Burden of Disease: From the Patient's Experience to a Socio-Economic View

5. Adolescent Perspectives on the Burden of a Parent's Migraine: Results from the CaMEO Study

Cited by 78 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of Ubrogepant on Patient-Reported Outcomes When Administered During the Migraine Prodrome;Neurology;2024-09-24

2. Evidence‐based review and frontiers of migraine therapy;Neurogastroenterology & Motility;2024-08-12

3. International Headache Society global practice recommendations for the acute pharmacological treatment of migraine;Cephalalgia;2024-08

4. CGRP Modulating Therapies: An Update;Current Neurology and Neuroscience Reports;2024-07-17

5. Bridging the Mind and Gut: Uncovering the Intricacies of Neurotransmitters, Neuropeptides, and their Influence on Neuropsychiatric Disorders;Central Nervous System Agents in Medicinal Chemistry;2024-04